DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Topical nepafenac after intravitreal injection: a prospective double-masked randomized controlled trial.

Author(s): Ulrich JN(1).

Affiliation(s): Author information: (1)Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina.

Publication date & source: 2014, Retina. , 34(3):509-11

PURPOSE: To evaluate if a single drop of nepafenac can reduce the ocular discomfort after intravitreal injections compared with placebo. METHODS: One hundred and twenty patients undergoing intravitreal injections of bevacizumab or ranibizumab received a drop of nepafenac or placebo (Systane Ultra) after the injection in a prospective, double-masked, randomized controlled design. Patients rated their pain levels from 0 to 3 (no pain, mild pain, moderate pain, severe pain) at 1 hour, 6 hours, and 24 hours after the procedure. RESULTS: Statistically significant reduction of postinjection pain with nepafenac was noted 6 hours after the injection when compared with placebo (0.8 ± 0.6 [standard deviation] vs. 1.3 ± 0.8, P < 0.001) with similar trends at 1 hour (1.1 ± 0.7 vs. 1.3 ± 0.7, P = 0.12) and 24 hours (0.3 ± 0.5 vs. 0.5 ± 0.6, P = 0.15). CONCLUSION: A single drop of nepafenac is effective in reducing discomfort after intravitreal injections.

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017